Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Imugene’s Azer-Cel Data Selected For Major Haematology Meeting

Imugene Limited (IMU) · Health care

IMU: $0.035 +16.67% · MC: $20M

Imugene said its azer-cel study of treatment alongside BTK inhibitors in relapsed or refractory B-cell cancers has been selected for a poster presentation at the American Society of Hematology’s annual meeting in December. The company plans to present emerging Phase 1b data; shares rose around 13% on the day, alongside the update.

Source announcements: 2026-11-05 15:27 to 2026-11-05 15:27 Sydney time
Story updated 2026-11-05 15:33 Sydney time
SourcesImugene selected for Poster Presentation at 2026 ASH Meeting
Comments